Cargando…

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease

Multiple lines of evidence confirm that the cumulative burden of low-density lipoprotein cholesterol (LDL-C) is causally related to the development of atherosclerotic cardiovascular disease (ASCVD). As such, lowering LDL-C is a central tenet in all ASCVD prevention guidelines, which recommend matchi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albosta, Michael S, Grant, Jelani K, Taub, Pam, Blumenthal, Roger S, Martin, Seth S, Michos, Erin D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332363/ https://www.ncbi.nlm.nih.gov/pubmed/37434791 http://dx.doi.org/10.2147/VHRM.S338424

Ejemplares similares

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
por: Nishikido, Toshiyuki
Publicado: (2023)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

High‐Sensitivity C‐Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study
por: Quispe, Renato, et al.
Publicado: (2020)

Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease’s ‘ABC’s Approach
por: Feldman, David I., et al.
Publicado: (2020)

Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
por: Dec, Adrianna, et al.
Publicado: (2023)

Accuracy of 23 Equations for Estimating LDL Cholesterol in a Clinical Laboratory Database of 5,051,467 Patients
por: Samuel, Christeen, et al.
Publicado: (2023)

Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
por: Desai, Nihar R., et al.
Publicado: (2022)

Lipid lowering with inclisiran: a real-world single-centre experience
por: Padam, Pritpal, et al.
Publicado: (2022)

Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
por: Rakocevic, Jelena, et al.
Publicado: (2023)

Inclisiran: a new generation of lipid-lowering siRNA therapeutic
por: Zhang, Yanzhen, et al.
Publicado: (2023)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
por: Ray, Kausik K, et al.
Publicado: (2022)

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
por: Makhmudova, U., et al.
Publicado: (2023)

Coronary artery calcium and atherosclerotic cardiovascular disease risk in women with early menopause: The Multi-Ethnic Study of Atherosclerosis (MESA)
por: Chu, Jian H., et al.
Publicado: (2022)

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
por: Ray, Kausik K, et al.
Publicado: (2022)

Practical, Evidence-Based Approaches to Nutritional Modifications to Reduce Atherosclerotic Cardiovascular Disease: An American Society For Preventive Cardiology Clinical Practice Statement
por: Belardo, Danielle, et al.
Publicado: (2022)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Inclisiran: a novel drug for the treatment of dyslipidemia
por: Nadeem, Abdullah, et al.
Publicado: (2023)

Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
por: Wilkinson, Michael J., et al.
Publicado: (2023)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies
por: Van Craeyveld, Eline, et al.
Publicado: (2011)

Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
por: Wong, Nathan D., et al.
Publicado: (2022)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Income disparity and utilization of cardiovascular preventive care services among U.S. adults
por: Shahu, Andi, et al.
Publicado: (2021)

Age-specific differences in patient reported outcomes among adults with atherosclerotic cardiovascular disease: Medical expenditure panel survey 2006–2015
por: Okunrintemi, Victor, et al.
Publicado: (2020)

Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient
por: Ueberdiek, Lars, et al.
Publicado: (2023)

Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology
por: Khera, Amit, et al.
Publicado: (2020)

Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies
por: Jeras, Jernej, et al.
Publicado: (2022)

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
por: Long, Sydney B, et al.
Publicado: (2011)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews
por: Li, Jiayi, et al.
Publicado: (2023)

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
por: Vohra, Laiba Imran, et al.
Publicado: (2023)

Corrigendum: Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient
por: Ueberdiek, Lars, et al.
Publicado: (2023)

Communication approaches to enhance patient motivation and adherence in cardiovascular disease prevention
por: Duffy, Eamon Y., et al.
Publicado: (2021)

The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
por: Narla, Venkata, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_4uhk5dq5sgij9dbvp0e54j0op0